Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Vaccine Adjuvants Market

ID: MRFR/Pharma/14018-HCR
100 Pages
Nidhi Mandole
Last Updated: April 24, 2026

US Vaccine Adjuvants Market Research Report: Size, Share, Trend Analysis By Types (Pathogen Component, Particulate Adjuvants, Others), By Route of Administration (Oral, Intramuscular, Subcutaneous, Intradermal) and By End Users (Pediatric, Adult) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Vaccine Adjuvants Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Pharmaceutical, BY Type (USD Million)
  49.     4.1.1 Alum
  50.     4.1.2 Monophosphoryl Lipid A
  51.     4.1.3 TLR Agonists
  52.     4.1.4 Saponins
  53.     4.1.5 Liposomes
  54.   4.2 Pharmaceutical, BY Application (USD Million)
  55.     4.2.1 Infectious Diseases
  56.     4.2.2 Cancer
  57.     4.2.3 Autoimmune Diseases
  58.     4.2.4 Allergies
  59.   4.3 Pharmaceutical, BY Route of Administration (USD Million)
  60.     4.3.1 Intramuscular
  61.     4.3.2 Subcutaneous
  62.     4.3.3 Intradermal
  63.     4.3.4 Oral
  64.   4.4 Pharmaceutical, BY End Use (USD Million)
  65.     4.4.1 Pharmaceutical Companies
  66.     4.4.2 Research Institutions
  67.     4.4.3 Contract Manufacturing Organizations
  68. 5 SECTION V: COMPETITIVE ANALYSIS
  69.   5.1 Competitive Landscape
  70.     5.1.1 Overview
  71.     5.1.2 Competitive Analysis
  72.     5.1.3 Market share Analysis
  73.     5.1.4 Major Growth Strategy in the Pharmaceutical
  74.     5.1.5 Competitive Benchmarking
  75.     5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  76.     5.1.7 Key developments and growth strategies
  77.       5.1.7.1 New Product Launch/Service Deployment
  78.       5.1.7.2 Merger & Acquisitions
  79.       5.1.7.3 Joint Ventures
  80.     5.1.8 Major Players Financial Matrix
  81.       5.1.8.1 Sales and Operating Income
  82.       5.1.8.2 Major Players R&D Expenditure. 2023
  83.   5.2 Company Profiles
  84.     5.2.1 GlaxoSmithKline (GB)
  85.       5.2.1.1 Financial Overview
  86.       5.2.1.2 Products Offered
  87.       5.2.1.3 Key Developments
  88.       5.2.1.4 SWOT Analysis
  89.       5.2.1.5 Key Strategies
  90.     5.2.2 Novartis (CH)
  91.       5.2.2.1 Financial Overview
  92.       5.2.2.2 Products Offered
  93.       5.2.2.3 Key Developments
  94.       5.2.2.4 SWOT Analysis
  95.       5.2.2.5 Key Strategies
  96.     5.2.3 Sanofi (FR)
  97.       5.2.3.1 Financial Overview
  98.       5.2.3.2 Products Offered
  99.       5.2.3.3 Key Developments
  100.       5.2.3.4 SWOT Analysis
  101.       5.2.3.5 Key Strategies
  102.     5.2.4 Merck & Co. (US)
  103.       5.2.4.1 Financial Overview
  104.       5.2.4.2 Products Offered
  105.       5.2.4.3 Key Developments
  106.       5.2.4.4 SWOT Analysis
  107.       5.2.4.5 Key Strategies
  108.     5.2.5 Pfizer (US)
  109.       5.2.5.1 Financial Overview
  110.       5.2.5.2 Products Offered
  111.       5.2.5.3 Key Developments
  112.       5.2.5.4 SWOT Analysis
  113.       5.2.5.5 Key Strategies
  114.     5.2.6 AstraZeneca (GB)
  115.       5.2.6.1 Financial Overview
  116.       5.2.6.2 Products Offered
  117.       5.2.6.3 Key Developments
  118.       5.2.6.4 SWOT Analysis
  119.       5.2.6.5 Key Strategies
  120.     5.2.7 Bristol-Myers Squibb (US)
  121.       5.2.7.1 Financial Overview
  122.       5.2.7.2 Products Offered
  123.       5.2.7.3 Key Developments
  124.       5.2.7.4 SWOT Analysis
  125.       5.2.7.5 Key Strategies
  126.     5.2.8 Bayer (DE)
  127.       5.2.8.1 Financial Overview
  128.       5.2.8.2 Products Offered
  129.       5.2.8.3 Key Developments
  130.       5.2.8.4 SWOT Analysis
  131.       5.2.8.5 Key Strategies
  132.     5.2.9 Seppic (FR)
  133.       5.2.9.1 Financial Overview
  134.       5.2.9.2 Products Offered
  135.       5.2.9.3 Key Developments
  136.       5.2.9.4 SWOT Analysis
  137.       5.2.9.5 Key Strategies
  138.   5.3 Appendix
  139.     5.3.1 References
  140.     5.3.2 Related Reports
  141. 6 LIST OF FIGURES
  142.   6.1 MARKET SYNOPSIS
  143.   6.2 US MARKET ANALYSIS BY TYPE
  144.   6.3 US MARKET ANALYSIS BY APPLICATION
  145.   6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  146.   6.5 US MARKET ANALYSIS BY END USE
  147.   6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
  148.   6.7 RESEARCH PROCESS OF MRFR
  149.   6.8 DRO ANALYSIS OF PHARMACEUTICAL
  150.   6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
  151.   6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
  152.   6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
  153.   6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
  154.   6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
  155.   6.14 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
  156.   6.15 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
  157.   6.16 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  158.   6.17 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
  159.   6.18 PHARMACEUTICAL, BY END USE, 2024 (% SHARE)
  160.   6.19 PHARMACEUTICAL, BY END USE, 2024 TO 2035 (USD Million)
  161.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  162. 7 LIST OF TABLES
  163.   7.1 LIST OF ASSUMPTIONS
  164.     7.1.1
  165.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  166.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  167.     7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  168.     7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  169.     7.2.4 BY END USE, 2025-2035 (USD Million)
  170.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  171.     7.3.1
  172.   7.4 ACQUISITION/PARTNERSHIP
  173.     7.4.1

US Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Million, 2025-2035)

  • Alum
  • Monophosphoryl Lipid A
  • TLR Agonists
  • Saponins
  • Liposomes

Pharmaceutical By Application (USD Million, 2025-2035)

  • Infectious Diseases
  • Cancer
  • Autoimmune Diseases
  • Allergies

Pharmaceutical By Route of Administration (USD Million, 2025-2035)

  • Intramuscular
  • Subcutaneous
  • Intradermal
  • Oral

Pharmaceutical By End Use (USD Million, 2025-2035)

  • Pharmaceutical Companies
  • Research Institutions
  • Contract Manufacturing Organizations

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓